Monique den Boer
Group Leader
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (3)
B-cell acute lymphoblastic leukemia (B-ALL) with high-hyperdiploidy (HHD) represents the most prevalent genetic subtype of childhood ALL. This retrospective international study aimed to identify the HHD subgroup(s) having both the highest proportion of B-ALL cases and the best outcome.Data from 11,530 B-ALL patients, including 3,231 with HHD-B-ALL, treated between 1998 and 2018 in eight trials from seven international Berlin-Frankfurt-Münster Group members were analyzed. Eight HHD subgroups – including double and triple trisomies, trisomy 18, UK-good-risk (UK-GR) profile, and four different modal chromosome number (MCN) categories – were evaluated for 5-year event-free survival (EFS), overall survival, and relapse. Each subgroup was ranked by outcome measures and prevalence within the B-ALL trial cohorts.HHD frequency ranged from 19–35%. MCN 54–67 and UK-GR profile achieved the lowest overall ranking scores corresponding to the largest (up to 28% for MCN 54–67 and 26% for UK-GR among total B-ALL trial cohorts) and best HHD subgroups (EFS ranged from 80.5–92.8% for MCN 54–67 and 80.5–93.5% for UK-GR).Both an MCN of 54–67 and UK-GR profile define large, reproducible subgroups of HHD B-ALL with good prognosis. They represent strong candidates for risk-stratification of treatment de-intensification trials in the modern immunotherapy era.
Year:
2025
PURPOSE Treatment stratification in ALL includes diverse (cyto)genetic aberrations, requiring diverse tests to yield conclusive data. We optimized the diagnostic workflow to detect all relevant aberrations with a limited number of tests in a clinically relevant time frame. METHODS In 467 consecutive patients with ALL (0-20 years), we compared RNA sequencing (RNAseq), fluorescence in situ hybridization (FISH), reverse transcriptase polymerase chain reaction (RT-PCR), karyotyping, single-nucleotide polymorphism (SNP) array, and multiplex ligation-dependent probe amplification (MLPA) for technical success, concordance of results, and turnaround time. RESULTS To detect stratifying fusions ( ETV6 :: RUNX1 , BCR :: ABL1 , ABL-class, KMT2A r, TCF3 :: HLF , IGH :: MYC ), RNAseq and FISH were conclusive for 97% and 96% of patients, respectively, with 99% concordance. RNAseq performed well in samples with a low leukemic cell percentage or low RNA quality. RT-PCR for six specific fusions was conclusive for >99% but false-negative for six patients with alternatively fused exons. RNAseq also detected gene fusions not yet used for stratification in 14% of B-cell precursor-ALL and 33% of T-ALL. For aneuploidies and intrachromosomal amplification of chromosome 21, SNP array gave a conclusive result in 99%, thereby outperforming karyotyping, which was conclusive for 64%. To identify deletions in eight stratifying genes/regions, SNP array was conclusive in 99% and MLPA in 95% of patients, with 98% concordance. The median turnaround times were 10 days for RNAseq, 9 days for FISH, 10 days for SNP array, and <7 days for MLPA and RT-PCR in this real-world prospective study. CONCLUSION Combining RNAseq and SNP array outperformed current diagnostic tools to detect all stratifying genetic aberrations in ALL. The turnaround time is <15 days matching major treatment decision time points. Moreover, combining RNAseq and SNP array has the advantage of detecting new lesions for studies on prognosis and pathobiology.
Year:
2025
Acute lymphoblastic leukemia (ALL) with fusions of ABL-class tyrosine kinase genes other than BCR::ABL1 occurs in ∼3% of children with ALL. The tyrosine kinase genes involved in this BCR::ABL1-like (Ph-like) subtype include ABL1, PDGFRB, ABL2, and CSF1R, each of which has up to 10 described partner genes. ABL-class ALL resembles BCR::ABL1-positive ALL with a similar gene expression profile, poor response to chemotherapy, and sensitivity to tyrosine kinase inhibitors (TKIs). There is a lack of comprehensive data regarding TKI sensitivity in the heterogeneous group of ABL-class ALL. We observed variability in TKI sensitivity within and among each ABL-class tyrosine kinase gene subgroup. We showed that ALL samples with fusions for any of the 4 tyrosine kinase genes were relatively sensitive to imatinib. In contrast, the PDGFRB-fused ALL samples were less sensitive to dasatinib and bosutinib. Variation in ex vivo TKI response within the subset of samples with the same ABL-class tyrosine kinase gene was not associated with the ALL immunophenotype, 5′ fusion partner, presence or absence of Src-homology-2/3 domains, or deletions of IKZF1, PAX5, or CDKN2A/B. In conclusion, the tyrosine kinase gene involved in ABL-class ALL is the main determinant of TKI sensitivity and relevant for specific TKI selection.
Year:
2024
Collaborators (8)
Sarah Tasian
Associate Professor
University of Pennsylvania
Gabriele Escherich
-
Anthony Moorman
Professor of Genetic Epidemiology
Newcastle University
Bastiaan Tops
Head of laboratory for childhood cancer pathology
Prinses Máxima Centrum voor Kinderoncologie
Arndt Borkhardt
Prof
Heinrich Heine University Düsseldorf
Judith Boer
Senior researcher
Princess Maxima Center
Andishe Attarbaschi
Medical University of Vienna
Amir Enshaei
Senior Lecturer
Newcastle University
Make your next move.
Prepare your application
Review drafts before you send them.